Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
Papp K, Adamski Z, Guenther L, Liljedahl M, Miasik-Pogodzinska A, Szponar-Bojda A, Lynde C, Nutt T, Mørch MH, Tyring S, Werschler W, Reich A, Sadick N, Turchin I, Lacour JP. Papp K, et al. Among authors: liljedahl m. J Dermatolog Treat. 2022 Jun;33(4):2297-2304. doi: 10.1080/09546634.2021.1959501. Epub 2021 Aug 9. J Dermatolog Treat. 2022. PMID: 34365872 Clinical Trial.
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M, Kircik L, Lacour JP, Liljedahl M, Lynde C, Mørch MH, Papp KA, Perrot JL, Gold LS, Takhar A, Thaçi D, Warren RB, Wollenberg A. Lebwohl M, et al. Among authors: liljedahl m. J Am Acad Dermatol. 2021 May;84(5):1269-1277. doi: 10.1016/j.jaad.2020.09.037. Epub 2020 Sep 18. J Am Acad Dermatol. 2021. PMID: 32950546 Free article. Clinical Trial.
Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.
Seyger M, Abramovits W, Liljedahl M, Hoejen MN, Teng J. Seyger M, et al. Among authors: liljedahl m. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2026-2034. doi: 10.1111/jdv.16233. Epub 2020 Feb 19. J Eur Acad Dermatol Venereol. 2020. PMID: 32074665 Free PMC article. Clinical Trial.
Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.
Eichenfield LF, Marcoux D, Kurvits M, Liljedahl M. Eichenfield LF, et al. Among authors: liljedahl m. J Eur Acad Dermatol Venereol. 2020 May;34(5):1098-1104. doi: 10.1111/jdv.16077. Epub 2020 Jan 2. J Eur Acad Dermatol Venereol. 2020. PMID: 31721327 Free PMC article. Clinical Trial.
Antigen presentation and T cell development in H2-M-deficient mice.
Fung-Leung WP, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, Webb SR, Karlsson L. Fung-Leung WP, et al. Among authors: liljedahl m. Science. 1996 Mar 1;271(5253):1278-81. doi: 10.1126/science.271.5253.1278. Science. 1996. PMID: 8638109
Altered antigen presentation in mice lacking H2-O.
Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, Teyton L, Peterson PA, Brunmark A, Rudensky AY, Fung-Leung WP, Karlsson L. Liljedahl M, et al. Immunity. 1998 Feb;8(2):233-43. doi: 10.1016/s1074-7613(00)80475-6. Immunity. 1998. PMID: 9492004 Free article.
35 results